Lv2
116 积分 2024-06-28 加入
Strategies and challenges for the next generation of antibody–drug conjugates
1个月前
已完结
Exploring the next generation of antibody-drug conjugates
1个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
4个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
5个月前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
6个月前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
6个月前
已完结
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer
6个月前
已完结
Survival with Cemiplimab in Recurrent Cervical Cancer
6个月前
已完结
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer
6个月前
已完结
皖公网安备34019202002308
